Market closed
Bio-Rad Laboratories/$BIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Ticker
$BIO
Sector
Trading on
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
7,700
ISIN
US0905722072
Website
BIO Metrics
BasicAdvanced
$6.5B
-
-$77.10
1.12
-
Price and volume
Market cap
$6.5B
Beta
1.12
52-week high
$373.69
52-week low
$215.38
Average daily volume
377K
Financial strength
Current ratio
5.994
Quick ratio
4.143
Long term debt to equity
19.867
Total debt to equity
20.503
Interest coverage (TTM)
5.64%
Management effectiveness
Return on assets (TTM)
1.55%
Return on equity (TTM)
-27.51%
Valuation
Price to revenue (TTM)
2.619
Price to book
0.99
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
20.038
Growth
Revenue change (TTM)
-2.46%
Earnings per share change (TTM)
591.77%
3-year revenue growth (CAGR)
-4.26%
3-year earnings per share growth (CAGR)
193.89%
What the Analysts think about BIO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.
BIO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BIO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BIO News
AllArticlesVideos
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
Business Wire·3 days ago
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Bio-Rad Reports First-Quarter 2025 Financial Results
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bio-Rad Laboratories stock?
Bio-Rad Laboratories (BIO) has a market cap of $6.5B as of May 15, 2025.
What is the P/E ratio for Bio-Rad Laboratories stock?
The price to earnings (P/E) ratio for Bio-Rad Laboratories (BIO) stock is 0 as of May 15, 2025.
Does Bio-Rad Laboratories stock pay dividends?
No, Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Bio-Rad Laboratories dividend payment date?
Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bio-Rad Laboratories?
Bio-Rad Laboratories (BIO) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.